Is ATHX or JNJ a better dividend investment in 2026?

ATHX currently yields 14814.81% with a 5% 5-year dividend growth rate. JNJ yields 3.36% with 5.8% growth. The better choice depends on your goal: ATHX offers higher current income.

What is the dividend yield difference between ATHX and JNJ?

ATHX has a forward dividend yield of 14814.81% ($2.00/share annually). JNJ yields 3.36% ($4.96/share annually). The yield gap is 14811.45 percentage points.

Home › Compare › ATHX vs JNJ

ATHX vs JNJ: Dividend Comparison 2026

ATHX yields 14814.81% · JNJ yields 3.36%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ATHX wins by $2677980877459223040.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ATHX

● Live price

14814.81%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2677980877459223040.00M

Annual income

$2,642,887,894,030,851,000,000,000.00

Full ATHX calculator →

JNJ

Johnson & Johnson

● Live price

3.36%

Share price

$147.50

Annual div

$4.96

5Y div CAGR

5.8%

Payout ratio

55%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.0K

Annual income

$827.78

Full JNJ calculator →

Portfolio growth — ATHX vs JNJ

📍 ATHX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ATHX	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ATHX + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ATHX pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATHX

Annual income on $10K today (after 15% tax)

$1,259,259.26/yr

After 10yr DRIP, annual income (after tax)

$2,246,454,709,926,223,300,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$285.83/yr

After 10yr DRIP, annual income (after tax)

$703.61/yr

At 15% tax rate, ATHX beats the other by $2,246,454,709,926,223,300,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATHX + JNJ for your $10,000?

ATHX: 50%JNJ: 50%

100% JNJ50/50100% ATHX

Portfolio after 10yr

$1338990438729611520.00M

Annual income

$1,321,443,947,015,425,400,000,000.00/yr

Blended yield

98.69%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ATHX

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Altman Z

-152.6

Piotroski

2/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

+55.1% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATHX buys

JNJ buys

No recent congressional trades found for ATHX or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricATHXJNJ

Forward yield	14814.81% ✓	3.36%
Annual dividend / share	$2.00	$4.96 ✓
Payout ratio	50% ✓	55%
1-year div growth	0%	4.2% ✓
5-year div CAGR	0%	5.8% ✓
Portfolio after 10y	$2677980877459223040.00M ✓	$20.0K
Annual income after 10y	$2,642,887,894,030,851,000,000,000.00 ✓	$827.78
Total dividends collected	$2675658490367706112.00M ✓	$5.6K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Buy	Buy

Year-by-year: ATHX vs JNJ ($10,000, DRIP)

Year	ATHX Portfolio	ATHX Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$1,492,181	$1,481,481.48	$10,676	$355.77	+$1.48M → ATHX
2	$208,198,432	$206,601,797.37	$11,407	$389.39	+$208.19M → ATHX
3	$27,163,301,697	$26,940,529,375.29	$12,198	$426.53	+$27163.29M → ATHX
4	$3,314,004,807,579	$3,284,940,074,762.82	$13,056	$467.62	+$3314004.79M → ATHX
5	$378,099,822,241,034	$374,553,837,096,924.30	$13,987	$513.12	+$378099822.23M → ATHX
6	$40,342,336,842,848,056	$39,937,770,033,050,150.00	$14,998	$563.56	+$40342336842.83M → ATHX
7	$4,025,655,551,654,171,600	$3,982,489,251,232,324,000.00	$16,098	$619.52	+$4025655551654.16M → ATHX
8	$375,711,296,730,478,150,000	$371,403,845,290,208,200,000.00	$17,295	$681.69	+$375711296730478.13M → ATHX
9	$32,797,180,774,179,380,000,000	$32,395,169,686,677,763,000,000.00	$18,599	$750.82	+$32797180774179380.00M → ATHX
10	$2,677,980,877,459,223,000,000,000	$2,642,887,894,030,851,000,000,000.00	$20,022	$827.78	+$2677980877459223040.00M → ATHX

ATHX vs JNJ: Complete Analysis 2026

ATHX — Stock

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Full ATHX Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →

📬

Get this ATHX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATHX vs SCHD ATHX vs JEPI ATHX vs O ATHX vs KO ATHX vs MAIN ATHX vs ABBV ATHX vs MRK ATHX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.